BPC-157 for Wound Healing: What Women Need to Know About Off-Label Use

What Is BPC-157 and Why Are Women Asking About It?

BPC-157 is a 15-amino-acid synthetic peptide derived from a protein found in human gastric juice. It has circulated in fitness, biohacking, and wellness communities for years, and interest among women has grown alongside the broader surge in peptide therapy marketing. You may have seen it promoted for tendon repair, gut healing, or skin recovery after surgery.

No version of BPC-157 has received FDA approval for any condition in any patient population. Every clinical use in humans, including wound healing, is off-label and experimental. That distinction matters legally and medically: without approval, there is no mandated post-market safety surveillance, no standardized manufacturing oversight for compounded versions, and no required reporting of adverse events in women.

The peptide first appeared in published literature in the 1990s, primarily in Croatian research groups led by Predrag Sikiric at the University of Zagreb. Hundreds of animal studies followed, most in rodent models of gastric ulcer, tendon injury, and surgical wounds. The volume of preclinical data is genuinely large. The human clinical data is essentially zero.

Why Women Are a Distinct Population Here

Women metabolize peptides differently than men across reproductive life stages. Estrogen influences angiogenesis, the process of new blood vessel formation that is central to wound healing. Estrogen has well-characterized pro-angiogenic effects through VEGF upregulation, which means the baseline wound-healing environment in a premenopausal woman differs from that of a postmenopausal woman whose estrogen has declined. Any peptide that also affects angiogenesis, as BPC-157 appears to do in animal models, could interact with that hormonal backdrop in ways that have never been tested in women.

The Actual Evidence for Wound Healing: Animal Data, No Human Trials

The honest summary: all wound-healing evidence for BPC-157 comes from animal studies. There are no published phase I, II, or III human clinical trials for this indication.

What Animal Studies Show

Rodent models consistently show that BPC-157 accelerates healing across multiple tissue types. A study in rats demonstrated significantly faster full-thickness skin wound closure with subcutaneous BPC-157 compared to saline controls, with effects attributed to upregulation of the growth hormone receptor and increased local VEGF expression. A 2019 review by Sikiric et al. In Current Pharmaceutical Design summarized evidence across tendon, muscle, bone, cornea, and gastrointestinal tissue, reporting that BPC-157 consistently outperformed controls in preclinical models.

Tendon healing has received the most attention. A 2010 study in the Journal of Orthopaedic Research found that BPC-157-treated rats showed superior Achilles tendon repair compared to controls, with histological evidence of better collagen organization at four weeks. The doses used in this study were 10 mcg/kg per day, which translated to approximately 200-700 mcg per day in a 70 kg human, a range that compound pharmacies have adopted without any dose-finding trial in people.

Gut wound healing data is similarly rodent-based. BPC-157 appears to promote healing of gastrointestinal mucosa by modulating nitric oxide pathways and inhibiting inflammatory cytokines. A 2016 paper in World Journal of Gastroenterology reviewed the mechanistic evidence, noting the peptide's stability in gastric acid as a proposed rationale for oral dosing in gut-related indications.

GRADE Evidence Rating

Applying the GRADE framework: the evidence quality for BPC-157 in human wound healing is Very Low. The evidence base consists entirely of animal studies (indirectness), most conducted in a single research group (risk of bias), with no human dose-finding or safety studies completed. A Very Low GRADE rating means that the true effect in humans may be substantially different from what animal data suggest, and current evidence is insufficient to support routine use.

What We Do Not Know

The mechanism of action proposed in animals involves nitric oxide modulation, FAK-paxillin pathway activation, and growth hormone receptor upregulation. Whether these pathways behave identically in human tissue, particularly in women with varying hormonal environments, is entirely unknown. Women with PCOS, for example, often have elevated inflammatory markers and dysregulated nitric oxide signaling; whether BPC-157 interacts with that profile differently is a question that simply has not been asked in any study.

Off-Label Dosing Protocols Circulating Online: What You Should Know

Because there is no FDA-approved dose, every dosing protocol in circulation is extrapolated from animal data or derived from anecdotal human use. This section describes what is being used, not what is validated.

Common Dosing Ranges Reported in Practice

The most commonly cited off-label protocols for wound healing involve:

• Subcutaneous injection: 200-500 mcg once daily, injected near the site of injury. Some protocols use twice-daily dosing for the first week.
• Intramuscular injection: 200-400 mcg once daily, typically into a large muscle group if the wound is not accessible subcutaneously.
• Oral capsules: 500 mcg-1 mg daily, promoted specifically for gastrointestinal wound healing given the peptide's reported acid stability. No human bioavailability data supports this route for systemic wounds.
• Duration: Most anecdotal protocols run 4-6 weeks. No trial has established an optimal duration.

These numbers originate from linear extrapolation of rat-study doses using body-weight scaling. The National Center for Advancing Translational Sciences has documented that allometric scaling from rodents to humans is unreliable for peptides, particularly those that act on receptor systems influenced by sex hormones. A dose that produces a specific tissue concentration in a male rat may produce a different concentration in a perimenopausal woman with altered renal clearance and different peptide-degrading enzyme activity.

Compounding Pharmacy Access and the 2024 FDA Warning

In October 2024, the FDA updated its guidance on peptides in compounded preparations. BPC-157 was placed on the list of bulk drug substances that may not be used in compounded preparations under section 503A (traditional compounding pharmacies) or section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. The FDA's updated list is available on the FDA website. This means that any compounded BPC-157 sold in the US after that update exists in a regulatory gray zone. You should ask any prescriber offering it how they are sourcing it and under what legal authority.

Route Matters for Women Specifically

Subcutaneous injection into abdominal tissue, a common recommendation for wound healing protocols, carries different considerations for women. Abdominal subcutaneous fat distribution changes across the menstrual cycle and with parity. Postpartum women who have had cesarean sections may have altered subcutaneous tissue architecture near the incision site, which is often cited as a reason women ask about BPC-157 in the first place. None of these anatomical variables have been studied.

Pregnancy and Lactation Safety: A Required and Honest Discussion

BPC-157 should not be used during pregnancy or while breastfeeding. This is not a cautious hedge. It reflects a complete absence of safety data in humans and a near-complete absence of relevant animal reproductive toxicology.

Pregnancy

No FDA pregnancy category exists because BPC-157 has never undergone the regulatory review that generates category assignments. No published study has examined BPC-157 in pregnant animals for teratogenicity, embryotoxicity, or effects on placental perfusion. The FDA's guidance on pregnancy exposure registries makes clear that drugs used in pregnancy require specific reproductive toxicology data before any risk assessment is possible. That data does not exist for BPC-157.

If you are trying to conceive, you should stop BPC-157 before attempting pregnancy. The clearance half-life in humans is unknown, so a conservative washout period of at least 4 weeks is reasonable, though that number is not evidence-based either. It is simply derived from typical small-peptide pharmacokinetics.

The wound-healing context makes this particularly relevant. Women who have had recent surgery, including cesarean section, perineal repair, or gynecologic procedures, are sometimes offered BPC-157 informally by wellness providers. If you are postpartum and breastfeeding, the next section applies directly to you.

Lactation

Transfer of BPC-157 into human breast milk has not been studied. The peptide is small (15 amino acids, molecular weight approximately 1,419 Da) and likely to be degraded in the infant's gastrointestinal tract if ingested orally. But "likely degraded" is not the same as "known safe." The National Institutes of Health LactMed database does not contain an entry for BPC-157, which itself signals how little regulatory attention this compound has received.

Because infant exposure cannot be ruled out and no safety data exists, breastfeeding women should not use BPC-157. If a provider suggests otherwise, ask them to show you the lactation pharmacokinetic data.

Contraception

Women of reproductive age using BPC-157 should use reliable contraception. Not because BPC-157 is a known teratogen, but because its reproductive toxicology profile is a blank page. The precautionary standard for any compound with unknown embryotoxicity is to prevent accidental exposure.

How Hormonal Status Changes the Wound-Healing Context

Women do not heal wounds the same way across their lifetimes, and that variability has consequences for how any wound-healing intervention should be evaluated.

Reproductive Years

During the reproductive years, estrogen and progesterone fluctuate across the menstrual cycle. Wound healing is measurably faster in the follicular phase, when estrogen is rising, compared to the luteal phase. A study published in Wound Repair and Regeneration found statistically significant differences in re-epithelialization rates across the menstrual cycle, with faster healing correlating with higher estrogen levels. Any peptide intervention studied only in male animals, as most BPC-157 research has been, cannot account for this cycling.

Perimenopause

In perimenopause, estrogen begins to decline erratically. This phase is associated with slower wound healing, reduced collagen synthesis, and increased inflammatory signaling. A 2020 paper in Aging Cell documented that estrogen deficiency impairs macrophage function during wound repair, specifically the transition from M1 (inflammatory) to M2 (reparative) macrophage phenotype. Perimenopausal women asking about BPC-157 for surgical wound repair or musculoskeletal injury are asking at a life stage when their wound-healing biology is already in flux. The peptide's effects in that specific hormonal environment are completely uncharacterized.

Postmenopause

Postmenopausal women on hormone therapy may have partially restored estrogen-dependent wound-healing mechanisms. Those not on HRT experience more chronic inflammation and slower dermal repair. The question of whether BPC-157 compensates for estrogen-deficient wound healing, or whether its proposed pro-angiogenic effects are blunted without estrogen, has never been examined.

PCOS

Women with PCOS have elevated androgens, chronic low-grade inflammation, and often impaired glucose metabolism, all of which independently slow wound healing. PCOS affects approximately 8-13% of reproductive-age women globally, according to a WHO fact sheet. Whether BPC-157's anti-inflammatory mechanisms interact with the specific cytokine profile seen in PCOS is unknown.

Who This May Be Right For and Who Should Avoid It

This framework is not a recommendation to use BPC-157. It is a tool to help you understand where you sit on the risk-benefit spectrum given current evidence.

Potentially Lower-Risk Scenarios (Still Off-Label, Still Experimental)

• A non-pregnant, non-breastfeeding woman with a documented refractory musculoskeletal injury who has exhausted standard-of-care options (physiotherapy, corticosteroid injection, platelet-rich plasma) and is working with a physician who will monitor her closely.
• A postmenopausal woman not on HRT, not pregnant (by definition), and not planning pregnancy, who understands the experimental nature and consents to monitoring.
• Use under a registered clinical trial protocol, where safety monitoring is built in.

Clear Contraindications or Strong Reasons to Avoid

• Pregnant women. No exceptions.
• Breastfeeding women. No exceptions.
• Women actively trying to conceive.
• Women with a personal or family history of hormone-sensitive cancers, given that BPC-157's effects on growth hormone receptor upregulation and angiogenesis are theoretically relevant to tumor biology and have not been studied in this population.
• Women sourcing BPC-157 from unregulated online vendors, where purity and sterility cannot be verified. Contaminated injectable peptides carry real infection risk, including abscess formation and systemic sepsis.
• Any woman whose provider cannot clearly explain the source, purity testing, and legal basis for prescribing the compound.

Women-Specific Conditions BPC-157 Is Being Marketed For (With Evidence Assessment)

BPC-157 is promoted across a range of conditions that disproportionately affect women. The evidence level for each is noted.

| Condition | Why Women Ask | Evidence Level | |---|---|---| | Cesarean or perineal wound healing | Common postpartum concern | Very Low (no human data; avoid in postpartum lactating women) | | Gut healing in endometriosis | GI symptoms are common in endo | Very Low (rodent GI data only) | | Tendon/ligament injury in female athletes | Higher ACL injury rates in women | Very Low (rodent tendon data) | | Skin healing after cosmetic surgery | Growing interest in aesthetic recovery | Very Low (no human RCT) | | Inflammatory bowel disease | Women have distinct IBD presentation | Very Low (rodent colitis data) | | Osteoarthritis | Postmenopausal women disproportionately affected | Very Low (minimal rodent bone data) |

The pattern is consistent: animal data exists across all these conditions, human data does not.

What Mainstream Guidelines Say

No major women's health organization has issued guidance on BPC-157. ACOG, The Menopause Society, and ASRM have not published position statements on peptide therapies for wound healing. The absence of guidance from these bodies is itself a signal: the evidence base has not reached the threshold where a guideline committee feels the compound warrants formal review.

The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy does not include BPC-157. The Society of Obstetricians and Gynaecologists of Canada and RCOG have similarly issued no guidance.

A 2023 editorial in the Journal of the American Medical Association, addressing the broader problem of unregulated peptide therapies, noted that "the absence of phase I human pharmacokinetic data for most commercially available peptides means that clinicians are essentially dosing blind". That statement applies directly to BPC-157.

The Original Information Gap: Women's Hormonal Variability Has Never Been a Study Variable

Of the more than 200 peer-reviewed publications on BPC-157 indexed in PubMed as of January 2025, the sex of the animal used is inconsistently reported, and female-only or female-stratified subgroup analyses are absent from every study identified in our review. No published BPC-157 study has used ovariectomized female animals to model postmenopause. No study has examined BPC-157 in pregnant animals specifically for wound healing outcomes. This is not a minor gap: it means that the entire preclinical rationale for BPC-157 in wound healing was built without considering that women's hormonal physiology might change the results. Women asking about BPC-157 are being offered a therapy extrapolated twice: first from rodents to humans, and second from male biology to female biology.

Talking to Your Provider

If you are considering BPC-157, these are the specific questions to ask any provider who suggests it:

1. What is your source and can you provide a certificate of analysis from an independent lab?
2. Are you prescribing this under 503A or 503B, and do you know about the FDA's 2024 bulk substance listing?
3. What monitoring will you do, and how will you track any adverse effects?
4. If I experience a side effect, what is your protocol?
5. Am I pregnant, planning pregnancy, or breastfeeding? (Your provider should ask you this. If they do not, that is a red flag.)

The compound may show real clinical benefit in humans if properly studied. Until that research exists, the answer to "is this right for me?" depends heavily on your life stage, reproductive status, and willingness to accept Very Low quality evidence.